Gastrointestinal Unit, University Federico II Naples, 80131 Naples, Italy.
World J Gastroenterol. 2013 Apr 28;19(16):2507-13. doi: 10.3748/wjg.v19.i16.2507.
To investigate the prevalence of human leukocyte antigen (HLA) DQ2/8 alleles in Southern Italians with liver and gastrointestinal (GI) diseases outside of celiac disease.
HLA DQ2/8 status was assessed in 443 patients from three ambulatory gastroenterology clinics in Southern Italy (University of Federico II, Naples, Loreto Crispi Hospital, Ruggi D'Aragona Hospital, Salerno). Patients were grouped based on disease status [pre-post transplant liver disease, esophageal/gastric organic and functional diseases, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)] and DQ2/8 alleles, which correspond to a celiac disease genetic risk gradient. Subject allele frequencies were compared to healthy Italian controls.
One hundred and ninety-six out of four hundred and forty-three (44.2%) subjects, median age 56 years and 42.6% female, were DQ2/8 positive. When stratifying by disease we found that 86/188 (45.7%) patients with liver disease were HLA DQ2/8 positive, 39/73 (53.4%) with functional upper GI diseases and 19/41 (46.3%) with organic upper GI diseases were positive. Furthermore, 38/105 (36.2%) patients with IBS and 14/36 (38.9%) with IBD were HLA DQ2/8 positive (P = 0.21). Compared to healthy controls those with functional upper GI diseases disorders had a 1.8 times higher odds of DQ2/8 positivity. Those with liver disease had 1.3 times the odds, albeit not statistically significant, of DQ2/8 positivity. Both those with IBS and IBD had a lower odds of DQ2/8 positivity compared to healthy controls.
The proportion of individuals HLA DQ2/8 positive is higher in those with liver/upper functional GI disease and lower in IBS/IBD as compared to general population estimates.
调查意大利南部非乳糜泻的肝脏和胃肠道（GI）疾病患者中人类白细胞抗原（HLA）DQ2/8 等位基因的流行情况。
在意大利南部三个门诊胃肠病学诊所（那不勒斯的 Federico II 大学、Loreto Crispi 医院、Ruggi D'Aragona 医院、Salerno）的 443 名患者中评估 HLA DQ2/8 状态。根据疾病状态[移植前后肝脏疾病、食管/胃器质性和功能性疾病、肠易激综合征（IBS）和炎症性肠病（IBD）]和 DQ2/8 等位基因对患者进行分组，这些等位基因对应于乳糜泻的遗传风险梯度。比较受试者等位基因频率与健康意大利对照。
443 名患者中有 196 名（44.2%），中位年龄 56 岁，42.6%为女性，为 DQ2/8 阳性。按疾病分层，我们发现 188 例肝脏疾病患者中有 86 例（45.7%）HLA DQ2/8 阳性，73 例功能性上 GI 疾病患者中有 39 例（53.4%）阳性，41 例器质性上 GI 疾病患者中有 19 例（46.3%）阳性。此外，105 例 IBS 患者中有 38 例（36.2%），36 例 IBD 患者中有 14 例（38.9%）HLA DQ2/8 阳性（P=0.21）。与健康对照组相比，功能性上 GI 疾病患者的 DQ2/8 阳性率高出 1.8 倍。患有肝病的患者 DQ2/8 阳性的几率高出 1.3 倍，但无统计学意义。与健康对照组相比，IBS 和 IBD 患者的 DQ2/8 阳性率较低。
与一般人群估计相比，HLA DQ2/8 阳性的个体在患有肝脏/上 GI 功能性疾病的人群中的比例较高，而在 IBS/IBD 中的比例较低。
